PSMA PET/CT
PSMA PET/CT is an intervention with 9 clinical trials. Currently 3 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
2 of 4 finished
50.0%
2 ended early
3
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
Clinical Trials (9)
Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
SUV on PSMA PET/CT in Non-Prostate Tumors
Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer
All 9 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 9